Ningbo Menovo TianKang Pharmaceutical Co., Ltd.

Macitentan tablets (specification: 10 mg) produced by Ningbo Minova Tiankang Pharmaceutical Co., Ltd. were used as the test preparation, and macitentan tablets (trade name: Apoquel®, specification: 10 mg) certified by Actelion Pharmaceuticals Ltd. were used as the reference preparation. The pharmacokinetic parameters of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent.

Primary objective: To compare the differences in absorption degree and speed between tranexamic acid tablets (specification: 0.5 g) provided by Ningbo Mennova Tiankang Pharmaceutical Co., Ltd. and certified tranexamic acid tablets (trade name: Tosamine®/Transamin®; specification: 0.5 g) of Daiichi Sankyo Co., Ltd. in healthy people under fasting and postprandial administration conditions. Secondary objective: To evaluate the safety of tranexamic acid tablets (specification: 0.5 g) provided by Ningbo Mennova Tiankang Pharmaceutical Co., Ltd. and certified tranexamic acid tablets (trade name: Tosamine®/Transamin®; specification: 0.5 g) of Daiichi Sankyo Co., Ltd. under fasting and postprandial administration conditions.

This trial aims to study the pharmacokinetic characteristics of ibrutinib capsules (140 mg) developed by Ningbo Minova Tiankang Pharmaceutical Co., Ltd. and produced by Jiangsu Huayang Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration in healthy subjects; using ibrutinib capsules (Yike®, 140 mg) certified by Janssen-Cilag International NV as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, the human bioequivalence of the two preparations was evaluated, and the safety of the two preparations in healthy subjects was observed.